A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial showed that patients receiving hormone therapy performed lower on processing speed ...

Arimidex is an aromatase inhibitor ... in postmenopausal women with disease progression, following tamoxifen therapy. Casodex is an androgen-receptor inhibitor, indicated for use in combination ...

The findings suggest that Fe-BNNPs could enhance drug delivery by improving stability, optimizing release mechanisms, and enabling targeted therapy. Anastrozole is a widely used aromatase inhibitor ...

Now, researchers have designed and synthesised new compounds that target the two enzymes. The new potential therapy is called a dual aromatase-steroid sulfatase inhibitor (DASI). Some of these new ...

Conversely, anastrozole therapy lowered estradiol levels, which did not revert to baseline between months 3 and 12; no such change was observed in the placebo group. Aromatase inhibition improved ...

The new potential therapy is called a dual aromatase-steroid sulfatase inhibitor (DASI). Some of these new compounds were found to effectively block both enzymes, which may help reduce estrogen ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...